Bio-Rad Laboratories, Inc. (BIO) Upgraded at TheStreet

TheStreet upgraded shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) from a c+ rating to a b- rating in a research note released on Monday morning.

A number of other research analysts also recently issued reports on BIO. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a hold rating to a sell rating in a research report on Thursday, August 10th. Deutsche Bank AG restated a buy rating and issued a $255.00 price target on shares of Bio-Rad Laboratories in a research report on Monday, September 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Bio-Rad Laboratories currently has a consensus rating of Buy and a consensus price target of $260.00.

Bio-Rad Laboratories (NYSE BIO) opened at $256.26 on Monday. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.06 and a quick ratio of 2.77. Bio-Rad Laboratories has a 52-week low of $169.19 and a 52-week high of $268.40. The stock has a market cap of $7,504.68, a PE ratio of 80.39, a PEG ratio of 3.82 and a beta of 0.88.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.37. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. The company had revenue of $535.00 million for the quarter, compared to the consensus estimate of $507.99 million. During the same period last year, the firm posted $0.62 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. research analysts anticipate that Bio-Rad Laboratories will post 2.65 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Bio-Rad Laboratories, Inc. (BIO) Upgraded at TheStreet” was first posted by BBNS and is owned by of BBNS. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://baseballnewssource.com/markets/bio-rad-laboratories-inc-bio-upgraded-at-thestreet/1780729.html.

In related news, EVP Giovanni Magni sold 2,400 shares of the stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $253.01, for a total value of $607,224.00. Following the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $2,340,595.51. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 28.29% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board acquired a new stake in shares of Bio-Rad Laboratories in the 2nd quarter worth about $113,000. Pacad Investment Ltd. acquired a new stake in shares of Bio-Rad Laboratories in the 2nd quarter worth about $113,000. First Manhattan Co. increased its holdings in shares of Bio-Rad Laboratories by 71.6% in the 3rd quarter. First Manhattan Co. now owns 599 shares of the medical research company’s stock worth $133,000 after acquiring an additional 250 shares during the period. Turner Investments LLC acquired a new stake in shares of Bio-Rad Laboratories in the 2nd quarter worth about $136,000. Finally, Meeder Asset Management Inc. increased its holdings in shares of Bio-Rad Laboratories by 3,333.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 618 shares of the medical research company’s stock worth $137,000 after acquiring an additional 600 shares during the period. 64.27% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.